Related references
Note: Only part of the references are listed.Effects of inorganic nitrate in a rat model of monocrotaline-induced pulmonary arterial hypertension
Eva Malikova et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2020)
Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension A Double-Blind Placebo-controlled Clinical Trial
R. James White et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2020)
Current Treatment Strategies and Nanoparticle-Mediated Drug Delivery Systems for Pulmonary Arterial Hypertension
Kazufumi Nakamura et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Therapy for Pulmonary Arterial Hypertension in Adults Update of the CHEST Guideline and Expert Panel Report
James R. Klinger et al.
CHEST (2019)
Prostacyclins in Cardiac Surgery: Coming of Age
Seema P. Deshpande et al.
SEMINARS IN CARDIOTHORACIC AND VASCULAR ANESTHESIA (2018)
Functions of PDE3 Isoforms in Cardiac Muscle
Matthew Movsesian et al.
JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE (2018)
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)
Nazzareno Galie et al.
EUROPEAN HEART JOURNAL (2016)
Beyond a single pathway: combination therapy in pulmonary arterial hypertension
Olivier Sitbon et al.
EUROPEAN RESPIRATORY REVIEW (2016)
Selexipag for the Treatment of Pulmonary Arterial Hypertension
Olivier Sitbon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension
N. Galie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The mechanistic basis of prostacyclin and its stable analogues in pulmonary arterial hypertension: Role of membrane versus nuclear receptors
Lucie H. Clapp et al.
PROSTAGLANDINS & OTHER LIPID MEDIATORS (2015)
Phosphodiesterase 5 inhibitors augment UT-15C-stimulated ATP release from erythrocytes of humans with pulmonary arterial hypertension
Elizabeth A. Bowles et al.
EXPERIMENTAL BIOLOGY AND MEDICINE (2015)
Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension
Irene M. Lang et al.
EUROPEAN RESPIRATORY REVIEW (2015)
Pharmacologic Therapy for Pulmonary Arterial Hypertension in Adults CHEST Guideline and Expert Panel Report
Darren B. Taichman et al.
CHEST (2014)
Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients Receiving Background Endothelin Receptor Antagonist and Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C2 Study) A Randomized Controlled Trial
Victor F. Tapson et al.
CHEST (2013)
Synergistic effects of prostacyclin analogs and phosphodiesterase inhibitors on cyclic adenosine 3′,5′ monophosphate accumulation and adenosine 3′5′ triphosphate release from human erythrocytes
Stephanie M. Knebel et al.
EXPERIMENTAL BIOLOGY AND MEDICINE (2013)
Hemodynamic Effects of Combination Therapy With Inhaled Nitric Oxide and Iloprost in Patients With Pulmonary Hypertension and Right Ventricular Dysfunction After High-Risk Cardiac Surgery
Theofani Antoniou et al.
JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA (2013)
Pulmonary Arterial Hypertension Epidemiology and Registries
Michael D. McGoon et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Riociguat for the Treatment of Pulmonary Arterial Hypertension
Hossein-Ardeschir Ghofrani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Pulmonary arterial hypertension
David Montani et al.
ORPHANET JOURNAL OF RARE DISEASES (2013)
Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: Treprostinil is a potent DP1 and EP2 agonist
Brendan J. Whittle et al.
BIOCHEMICAL PHARMACOLOGY (2012)
Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients on Background Endothelin Receptor Antagonist and/or Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C Study) A Randomized Controlled Trial
Victor E. Tapson et al.
CHEST (2012)
Dietary Nitrate Ameliorates Pulmonary Hypertension Cytoprotective Role for Endothelial Nitric Oxide Synthase and Xanthine Oxidoreductase
Reshma S. Baliga et al.
CIRCULATION (2012)
REVEAL: a contemporary US pulmonary arterial hypertension registry
M. D. McGoon et al.
EUROPEAN RESPIRATORY REVIEW (2012)
Combination therapy for the treatment of pulmonary arterial hypertension
Andrew T. Levinson et al.
Therapeutic Advances in Respiratory Disease (2011)
Addition of Inhaled Treprostinil to Oral Therapy for Pulmonary Arterial Hypertension A Randomized Controlled Clinical Trial
Vallerie V. McLaughlin et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension
Kamal K. Mubarak
RESPIRATORY MEDICINE (2010)
Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial (vol 149, pg 521, 2008)
G. Simonneau et al.
ANNALS OF INTERNAL MEDICINE (2009)
Combination therapy with prostacyclin and tadalafil for severe pulmonary arterial hypertension: A pilot study
Daniele Bendayan et al.
RESPIROLOGY (2008)
Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension
Robert Voswinckel et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2008)
Addition of Sildenafil to Long-Term Intravenous Epoprostenol Therapy in Patients with Pulmonary Arterial Hypertension A Randomized Trial
Gerald Simonneau et al.
ANNALS OF INTERNAL MEDICINE (2008)
Physiology and pathophysiology of prostanoid receptors
Shuh Narumiya
PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES (2007)
2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug
Keiichi Kuwano et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
The nitric oxide/cGMP signaling pathway in pulmonary hypertension
James R. Klinger
CLINICS IN CHEST MEDICINE (2007)
Prostanoid receptors in the human vascular wall
Xavier Norel
THESCIENTIFICWORLDJOURNAL (2007)
Efficacy of sildenafil as a rescue therapy for patients with severe pulmonary arterial hypertension and given long-term treatment with prostanoids: 2-year experience
Maria Jose Ruiz et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2006)
Tonic and acute nitric oxide signaling through soluble guanylate cyclase is mediated by nonheme nitric oxide, ATP, and GTP
SPL Cary et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Cellular and molecular pathobiology of pulmonary arterial hypertension
M Humbert et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2004)
Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension
HA Ghofrani et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2003)
Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension
HA Ghofrani et al.
ANNALS OF INTERNAL MEDICINE (2002)
Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension
H Wilkens et al.
CIRCULATION (2001)
Short-term oval administration of L-arginine improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension
N Nagaya et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2001)
Nitric oxide and molsidomine in the management of pulmonary hypertension in Takayasu's arteritis
SD Lee et al.
CHEST (2001)
Share Paper
